• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Apply for the Fierce AI Innovation Awards - Submissions close Thursday, June 18

GLP-1

Mike Doustdar Novo Nordisk Novo Novo CEO
Favicon Fierce Pharma

Novo Nordisk’s ‘optimistic’ CEO Doustdar sits down with Fierce

Novo Nordisk CEO Mike Doustdar told Fierce in an interview that he always believed the Big Pharma “did actually need to become more competitive.”
Fraiser Kansteiner Jun 11, 2026 7:00am
Brown mouse nibbling a cookie

GLP-1s may combat depression through a mood-boosting gut microbe

Jun 10, 2026 11:00am
AZ

ADA: AZ’s oral GLP-1 shows ‘competitive efficacy’ in phase 2

Jun 9, 2026 9:48am
Boehringer Ingelheim ADA2026 BI

ADA: Tolerability questions linger for Boehringer's obesity drug

Jun 8, 2026 4:30am
Lilly ADA

ADA: Lilly offers deeper glimpse into triple-G obesity candidate

Jun 6, 2026 3:28pm
Pfizer ADA

ADA: Pfizer pads case for berobenatide in obesity

Jun 6, 2026 9:29am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings